The Study on the Involvement of Periostin in the Pathophysiology of Atopic Canine Skin

イヌのアトピーの皮膚におけるペリオスチンの病態への関与に関する研究

2016年2月

麻布大学大学院 獣医学研究科
獣医学専攻 博士課程
DV1206 峰重 隆幸
Abstract

Introduction

Canine atopic dermatitis (cAD) is a common, pruritic and allergic skin disease of dogs that shares several clinicopathological features with human atopic dermatitis (hAD). In hAD, periostin (PO) is assumed to play a critical role in the enhancement and chronicity of allergic skin inflammation; however, the pathogenesis of cAD involved of PO has been unknown. Also, the inducer of PO in the canine skin has not been clarified. Therefore in Chapter 1, the author investigated the expression of the PO protein and mRNA in healthy, atopic, and nonatopic inflamed skin in dogs. In Chapter 2, the author focused on IL-13 and TGF-β1 which were assumed to be inducing factor of PO, using skin tissues of cAD as well as canine cultured keratinocytes and dermal fibroblasts. Next, the function of PO was examined using culture canine keratinocytes by proliferation assay, microarray and real time quantitative RT-PCR.

Chapter 1: Expression of Periostin in Normal, Atopic, and Nonatopic Chronically Inflamed Canine Skin

Canine Skin

The aim of this chapter was to examine the expression patterns of PO in healthy, atopic, and nonatopic chronically inflamed canine skin. Biopsy specimens from 47 dogs with skin disease, and normal skin tissue from 5 adult beagles were examined by light microscopy,
immunohistochemistry (IHC), and *in situ* hybridization (ISH). In normal skin, PO was localized just beneath the epidermis and around the hair follicles. In chronically inflamed skin, PO expression was most intense in the dermis with inflammatory cell infiltrates. In contrast, low levels of PO were detected in acutely inflamed and noninflamed skin. Conversely, all cAD tissues characteristically showed the most intense expression of PO in the superficial dermis.

ISH showed that PO mRNA was broadly expressed in the basal epidermal keratinocytes, outer root sheath cells, and dermal fibroblasts in normal dog skin. High expression of PO mRNA was observed in fibroblasts in dog skin with chronically inflamed dermatitis. Moreover, in some chronically inflamed skin specimens, PO mRNA expression was increased in basal keratinocytes. The severity score of chronic pathological changes and CD3+ cell number in the dermis were correlated with distribution pattern of PO in the atopic skin. These data suggest that PO is able to play a role in the pathophysiology of chronic dermatitis, including cAD.

*Chapter 2: Involvement of IL-13 in the Induction of Periostin, and Effect of Periostin on Keratinocytes*

From the results of Chapter 1, it was suggested that PO might be involved in the pathogenesis of chronicity in cAD. Therefore, the author tried to clarify the mechanism of the amplification and chronicity of dermal inflammation by PO in canine atopic skin in this chapter. By
double-labeled ISH. IL-13 mRNA positive cells were detected near the keratinocytes and fibroblasts expressing PO mRNA in the dermis of atopic skin. TGF-β1 mRNA positive cell was not seen in all atopic skins. By *in vitro* assay, IL-13 induced the gene expression of PO in both canine dermal fibroblasts and keratinocytes. PO enhanced *in vitro* growth of canine keratinocytes. Moreover, among the PO-induced genes in cultured canine keratinocytes detected by microarray, the author identified IL-25 and KDAP as possible mediators in canine atopic skin. Also, real time PCR analysis revealed up-regulation of both IL-25 and KDAP gene expression in PO-stimulated keratinocytes. These data suggest that IL-13 possibly derived from Th2 cells stimulates PO production in both keratinocytes and fibroblasts, and then PO may play a critical role in the pathophysiology of cAD, especially in the enhancement and chronicity of skin lesion via IL-25 and KDAP.

**Conclusion**

The author proposed a novel hypothesis that PO induced by IL-13 contributes to the enhancement and chronicity of allergic skin inflammation in canine atopic skin. The findings of the present study provide a molecular basis for considering PO and IL-13 as a potential therapeutic targets for cAD.
Contents

Abstract ....................................................................................................................... 2

General Introduction ................................................................................................. 7

Chapter 1: Expression of Periostin in Normal, Atopic, and Nonatopic
Chronically Inflamed Canine Skin ........................................................................... 10

  Introduction ........................................................................................................... 10

  Materials and Methods ......................................................................................... 11

  Results .................................................................................................................. 17

  Discussion ............................................................................................................. 20

  Figures and Tables ............................................................................................... 23

Chapter 2: Involvement of IL-13 in the Induction of Periostin, and Effect of
Periostin on Keratinocytes ..................................................................................... 37

  Introduction ........................................................................................................... 37

  Materials and Methods ......................................................................................... 38

  Results .................................................................................................................. 41

  Discussion ............................................................................................................. 43

  Figures and Tables ............................................................................................... 47

Conclusion .............................................................................................................. 53
General Introduction

Atopic dermatitis (AD) is a chronic, pruritic and allergic skin disease in humans as well as animals, especially dogs. Classically, AD has been believed to associate with high specific IgE against environmental allergens, such as house dust mite (HDM). Recently, AD has been recognized as a multifaceted disease resulting from a complex interaction between environmental and genetic factors.

Canine atopic dermatitis (cAD) has been focused as a spontaneous atopic animal model, because dogs live in human lifestyle environment, and cAD shares several clinicopathological features with human atopic dermatitis (hAD), including age of onset, skin areas affected, severe pruritus, and the immunopathological mechanism.[13, 18, 23] Histologically, the skin lesion in hAD and cAD is characterized by spongiotic dermatitis with mononuclear infiltrate composed of T lymphocytes. [19, 23] In addition, both hAD and cAD are characterized by allergic inflammation due to the release of various cytokines, mainly T helper 2 (Th2) cytokines such as interleukin (IL)-4 and IL-13.[18, 21, 23]

In AD, once allergic inflammation is triggered by exposure to allergens, the skin lesion chronically persists without continuous allergen stimulation. Therefore, chronic inflammation irritation and epidermal hyperplasia are major pathological problems of hAD and cAD.

However, the mechanisms underlying chronicity in allergic inflammation and associated skin
reaction remain unknown.

Periostin (PO) is an extracellular matrix (ECM) protein that belongs to the fasciclin family.[15, 20, 31] PO was first described as osteoblast-specific factor 2 (OSF-2) in 1993 as a homophilic adhesion molecule in bone formation.[25] PO modulates cell function by binding to integrin molecules on the cell surface; thus, providing signals for tissue development and remodeling.[6, 20, 31, 32] The production of PO is induced by transforming growth factor (TGF)-β as well as interleukin-4 and IL-13, which are signature cytokines of the Th2-type immune response in bronchial asthma, suggesting the involvement of PO in allergic inflammation.[7, 14, 31] Recently, Masuoka et al.[14] reported that deficiency of PO suppressed allergic inflammation induced by treatment with HDM extract in atopic model mice. They further indicated that PO bound to αv integrin on mouse keratinocytes in vitro, which resulted in the induction of proinflammatory cytokines, including thymic stromal lymphopoietin (TSLP). Thus, PO may play a critical role in the enhancement and chronicity of allergic skin inflammation in hAD and experimental atopic models. However, only one report described a significant alteration of the gene expression of PO in atopic skin compared with healthy skin in dogs by real time reverse transcription polymerase chain reaction (RT-PCR).[29]

In this study, the author tried to clarify the involvement of PO in canine atopic skin using skin tissues of cAD as well as canine cultured keratinocytes and dermal fibroblasts. The findings of
this study may provide a molecular basis for considering PO as potential therapeutic targets for cAD.
Chapter 1: Expression of Periostin in Normal, Atopic, and Nonatopic Chronically Inflamed Canine Skin

Introduction

PO is highly expressed in the skin of hAD patients and is correlated with disease severity on histological examination. Recently, using PO-deficient mice, Masuoka et al.[14] reported that a lack of PO results in failed development of allergic skin inflammation caused by sensitization to inhaled allergens. However no reports described the location of PO in canine health and atopic skin.

Previous *in vitro* analyses demonstrated that dermal fibroblasts produced and secreted PO, which is depending on cytokine stimulation via integrin signaling. In AD lesions, it is suspected that fibroblasts are the main source of PO, although it has not been confirmed by *in vivo* analysis.[14, 22, 26]

It is important to reveal the localization of PO and PO producing cells in normal and affected skin, because we have to discuss the involvement of PO in canine atopic skin. First, the author examined the expression of the PO protein in healthy, atopic, and nonatopic inflamed skin in dogs. Then, the author examined the localization of PO mRNA by *in situ* hybridization (ISH) in these skin tissues. Finally, the author discussed a part of role of PO in the pathophysiology in canine atopic skin.
Materials and Methods

RNA extraction from normal skin and other tissues, RT-PCR, TA cloning, Sequence analysis

The normal canine tissues including heart, lung, liver, kidney, spleen, small intestine, large intestine, ovary, testis, cerebrum, lymphatic node and skin from two adult beagles (one male and one female, aged 1–7 years) were used as qualitative RT-PCR samples. Total RNA was extracted from normal tissues using the TRIzol reagent (Invitrogen Life Technologies, Carlsbad, CA). Extracted total RNA was treated with RNase-free DNase (Promega, Madison, WI) and used in RT-PCR employing the SuperScript III First-Strand Synthesis System (Invitrogen Life Technologies). Primer sequences were obtained by determining the predicted mRNA sequences of Canis lupus familiaris PO (NCBI database accession number: XM_003433308). The primer sequences were as follows: canine PO forward, 

5’CAGCTCAGAGTCTTTGTCTACTGATACAG3’; and reverse, 

5’CTCCTGCTGTAGTGTGAAGTAGT3’. PCR reaction with KOD FX Neo (Toyobo, Osaka, Japan) was performed as follows: denaturation at 94 °C for 5 min; 30 cycles of denaturation at 98 °C for 10 s, annealing at 66 °C for 30 s, and extension at 68 °C for 30 s; and a final extension step at 68 °C for 30 s.

The gene fragment of skin was cloned into the pTA2 vector (Toyobo) using a TAready
clone-Plus-TA cloning kit (Toyobo). The partial sequences of PO were cloned into One Shot® TOP10 Chemically Competent Escherichia coli (Invitrogen Life Technologies). The precipitated DNA was sequenced and analyzed by TaKaRa Bio (Shiga, Japan) using a 3730xl DNA Analyzer (Applied Biosystems, Foster city, CA).

Skin Biopsies

The skin tissues obtained from the chest region of normal 5 dogs (two males and three females, aged 1–7 years) were used as controls (Azabu university experimental animal committee, No.100408-3).

The clinical data and pathological diagnoses of 47 dogs of various breeds included in the present study are listed in Table 1. Their ages ranged from 4 months to 17 years, and the cohort included 27 males, 19 females, and one dog for which the sex was not documented. A total of 62 biopsies were taken from the 47 dogs with skin diseases. Skin punch biopsies were fixed in 10% neutral-buffered formalin, embedded in paraffin, cut, and stained with hematoxylin and eosin (HE).

The skin diseases included in the present study were divided into three groups: chronic dermatitis (inflammatory skin disease with acanthosis and dermal fibrosis) (case Nos. 1–41), acute dermatitis (case Nos. 42 and 43), and noninflamed skin disease (case Nos. 44–47).
Chronic skin diseases included cAD (n = 9), sebaceous adenitis (n = 4), superficial pyoderma (n = 2), pemphigus foliaceus (n = 2), deep pyoderma (n = 2), and sterile pyogranuloma (n = 2).

The pathological diagnosis was based on clinical and light microscopic features. The diagnosis of cAD was based on the clinical criteria proposed by Terada.[27]

Reverse transcription (RT) for real time PCR was performed on samples from 5 lesion sites of 4 atopic dogs (site Nos. 3, 4, 7, 18, and 19). One half of each skin sample was fixed in 10% neutral-buffered formalin, embedded in paraffin, cut, stained with HE, and subjected to IHC and ISH. The second half of each specimen was embedded in optimal cutting temperature (OCT) compound (Sakura Finetek, Tokyo, Japan), and the block embedded in OCT compound was snap-frozen and maintained at −80 °C. Ten sections of each specimen, 10 μm in thickness, were cut on a cryostat at −20 °C and immersed into RNAse-free 1.5-ml microcentrifuge tubes containing Buffer RLT Plus (Qiagen, Hilden, Germany). Total RNA was extracted from each specimen using the RNeasy Plus Micro Kit (Qiagen). Extracted total RNA was used in quantitative RT-PCR employing the SuperScript® VILO™ cDNA Synthesis Kit (Invitrogen Life Technologies).

**Immunohistochemistry**

Immunohistochemistry (IHC) was performed using the immunoenzyme polymer method and
the primary polyclonal or monoclonal antibodies shown in Table 2. After incubation with 4% BlockAceTM (Yukijirushi, Sapporo, Japan) for 10 min at room temperature, dewaxed sections were incubated overnight with the antibodies against PO at 4 °C. Peroxidase-conjugated anti-mouse (Histofine Simple Stain MAX-PO (M), Nichirei, Tokyo, Japan) or anti-rabbit (EnVision+™, Dako Corp., Glostrup, Denmark) immunoglobulin (Ig)G were used as secondary antibodies. After the immunoreaction, the sections were colorized with diaminobenzidine (DAB) and counterstained with Mayer’s hematoxylin. Non-immune mouse or rabbit IgG was used in place of the primary antibody as a negative control.

Immunofluorescence assay was performed using anti-type IV collagen, anti-laminin, and anti-PO antibodies. FITC-conjugated goat anti-rabbit IgG (EY Laboratories, San Maeto, CA) was used this assay. Immunofluorescence was analyzed using an FSX100 fluorescence microscope (Olympus, Tokyo, Japan).

For quantitative morphometric analysis, the localization and distribution of PO were assessed within four areas of the skin: the epidermal–dermal junction (EDJ), which constitutes an anatomic functional unit containing the basement membrane; the perifollicular area (PF), including the follicular basement membrane and the connective tissue follicle; the superficial dermis (SD), the top layer of the dermis normally composed of thin collagen fibers; and the deep dermis (DD), the thin bottom layer of the dermis normally composed of thick collagen
fibers. Within each area, the expression of PO was assessed semiquantitatively and scored as follows: 0 = no expression, 1+ = weak expression, 2+ = moderate expression, 3+ = high expression. In cAD cases, the three distribution patterns of PO in the skin were defined, as follows (compared with the normal control, which was assigned a normal pattern): basement membrane (BM) pattern (weak-to-moderate expression in EDJ and PF); superficial pattern (high expression in EDJ or weak expression in SD); diffuse pattern (moderate expression in SD or expression in DD); as shown in Table 3. Epidermal thickness was measured; the number of CD3-positive cells (T cells), CD20-positive cells (B cells), and mast cells in the SD were counted in 10 randomly selected high-power fields for each sample and their average values were calculated. Dermal fibrosis was semiquantitatively assessed to evaluate the severity of chronic pathological changes as follows: no (0), mild (1+), moderate (2+), and severe (3+).

*In situ hybridization*

Gene-specific probe sets for canine mRNA consisting of an average of 20 different probe pairs were custom designed and synthesized by Affymetrix (Santa Clara, CA). PO probes were used in type 1/Fast Red.

Single ISH for PO was performed on samples from 21 dogs (case Nos. 1–7, 10, 11, 15, 17, 18, 21, 22, 24, 31, 32, 36, 37, 42 and 43) using the QuantiGene® ViewRNA ISH Tissue Assay
(Affymetrix) according to the manufacturer’s protocol. The signal for PO mRNA was visualized with fast red and counterstained with Gill’s hematoxylin. A canine PO mRNA sense probe or an ISH reaction solution without the probes was used as a negative control, according to Affymetrix’s recommendations.

Real time quantitative RT-PCR

Quantification of PO and GAPDH (glyceraldehyde-3-phosphate dehydrogenase) mRNA expression was performed using StepOne™ Real-Time PCR Systems (Applied Biosystems) and TaqMan Universal PCR Master Mix (Applied Biosystems), with sample cDNA in a final volume of 20 μl per reaction. Canine PO mRNA primers and probes were designed by Applied Biosystems and supplied as TaqMan Gene Expression Assays Mix containing a 20× mix of unlabeled PCR forward and reverse primers, as well as a TaqMan MGB probe (Assay ID: Cf02680558_m1). The PCR reaction of PO mRNA was performed in duplicate for each sample and mean values of the gene expression were calculated as a ratio to those of GAPDH according to the ΔΔCT method.

Statistical analyses

Statistical analyses of distribution patterns of PO and histological scores were performed using
GraphPad Prism (ver. 5.0, GraphPad Software, La Jolla, CA). One-way ANOVA was performed to analyze the difference between distribution patterns of PO and histological scores, and significant differences were identified using the Tukey–Kramer test. Comparisons of mRNA extracted from between atopic and normal dog groups in analysis of PO mRNA expression were performed by the Mann–Whitney U-test. P values of <0.05 were considered statistically significant.

Results

Expression of the PO gene in normal skin tissues

RT-PCR was performed to assess the expression level of the PO mRNA (346 bp) in various canine tissues, including heart, lung, liver, kidney, spleen, pancreas, small intestine, colon, ovary, testis, cerebrum, mesenteric lymph node and skin. The PO mRNA was expressed in a wide range of normal canine tissue (Figure 1a). Canine GAPDH (219 bp) cDNA was amplified as an internal control (Figure 1b).

The sequence of PO mRNA extracted from canine skin was registered in the DNA Data Bank of Japan (DDBJ) (Accession number LC008358). Sequence analysis of the amplification product showed homology to the partial sequences of predicted canine PO mRNA (100%) and human PO mRNA (92%).

ISH revealed that PO mRNA-positive cells were located in the outer root sheath (ORS),
particularly in the outer cells along the basement membrane, whereas there was a small number
of signals in the ORS inner cells in normal dog skin (Figure 2a). The PO protein was located at
the basement membrane of hair follicles in normal dog skin (score 1+) (Figure 2b). In the
epidermis, PO mRNA was expressed only in the basal epidermal keratinocytes (Figure 2c). The
PO protein was detected at low level in the EDJ (score 1+) (Figure 2d) but not in DD (score 0).
The signals were not detected in tissues that underwent the procedure using the sense probe or
the ISH solution without the probe (Figure 2e). PO protein was not detected in the cells. No
specific staining was observed with non-immune rabbit IgG (Figure 2f).

*PO highly deposited in the atopic dermis.*

The results of the immunohistochemical examination of skin diseases are summarized in Table
1. PO protein expression in chronically inflamed skin was most intense in the dermis with
inflammatory cell infiltrates (scores 1+, 2+ or 3+) (Figures 3a, 3b, 4a, 4b, 5a, and 5b), whereas
low levels of PO were detected in acutely inflamed and noninflamed skin diseases. Sebaceous
adenitis was characterized by the destruction of the sebaceous gland and was associated with an
intense expression of PO in the superficial dermis, particularly at PF. In diffuse dermatitis, PO
protein expression was intense throughout the dermis. In sterile pyogranuloma, both
inflammatory cells and PO protein expression were observed in DD and subcutaneous tissue.
Among the inflammatory skin diseases, all canine AD tissues characteristically showed the most intense expression of PO in the superficial dermis, particularly at EDJ (2+ or 3+) (Figure 6a). Expression of type IV collagen and laminin was detected at the EDJ and vascular basement membrane (Figure 7a, b). PO was more prominently expressed at the EDJ and detected faintly at the vascular basement membrane (Figure 7c). No staining was observed with non-immune rabbit IgG (Figure 6c).

Keratinocytes and dermal fibroblasts are the main source of PO in cAD.

Positive signals for PO mRNA were detected in spindle-shaped stromal cells in the inflammatory areas (Figures 3c, 4c, and 5c), together with protein expression. These stromal cells were positive for vimentin and negative for factor VIII-related antigen and smooth muscle actin, indicating that most of the stromal cells were fibroblasts. In addition, the PO mRNA was expressed in some adipocytes. In six (case Nos. 3, 5, 10, 15, 24, and 32) out of 21 dogs, increased PO mRNA expression was observed more clearly in epidermal keratinocytes (Figure 6b). Signals were not detected in tissues that underwent the procedure using the sense probe or the ISH solution without the probe (Figure 6d).

Real time RT-PCR using total RNA from frozen sections showed no significant difference in PO
*mRNA expression between atopic and control skin groups.*

Real time RT-PCR using total RNA from sections of five lesion sites in 4 atopic dogs showed no significant difference in the ratio of PO/GAPDH mRNA expression between atopic and control skin groups (Figure 8).

*PO deposition score was correlated with histopathological severity of cAD.*

The distribution patterns of PO were correlated with chronic pathological changes and the number of CD3+ cells in the skin tissues of atopic dogs. Chronic pathological changes (epidermal thickening and fibrosis) and the number of CD3+ cells in the skin were significantly different between some distribution patterns of PO, especially in normal and diffuse patterns. Although there were no significant differences in the number of CD20+ cells and mast cells between the different distribution patterns of PO (Table 3 and Figure 9).

Discussion

To the best of my knowledge, this study was the first report showing the expression patterns of PO mRNA and protein in various spontaneous skin diseases of dogs. The author found that, in normal canine skin, similarly to that in human and murine skin, PO mRNA was expressed only in the basal epidermal keratinocytes, outer root sheath cells, and dermal fibroblasts and that PO was deposited just beneath the epidermis and around the hair follicles. Furthermore, the
distribution pattern of PO mRNA and protein in normal and inflamed skin appeared to be significantly different. An increased expression of PO was observed in chronically inflamed skin compared with normal, noninflamed, and acutely inflamed skin. In the present study, the author confirmed that cAD is characterized by the expression of PO in the superficial dermis, particularly at EDJ. PO was partially colocalized with other ECM such as type IV collagen and laminin components of the basement membrane. Moreover, the severity of chronic pathological changes and infiltration of CD3+ cells in the dermis were different between distribution patterns of PO, especially between normal and diffuse pattern. In atopic dogs, T cells are major components of the inflammatory cell infiltrate in the skin.[8] Th2 cytokines play a critical role in inducing allergic inflammation in addition to promoting IgE class switching.[18, 21, 23]

The author has identified PO-producing cells within the canine atopic skin and proposes that these cells are fibroblasts. Conversely, in some atopic canine skin, PO mRNA was notably expressed in keratinocytes. Nishiyama et al.[16] showed that PO mRNA was temporarily expressed not only in fibroblasts but also in keratinocytes in hair follicles during wound healing. To the best of our knowledge, to date, no reports have focused on PO production by epidermal cells in human and canine atopic skin.[14, 22, 26, 31]

Real time RT-PCR using total RNA from frozen sections, the ratio of PO/GAPDH mRNA expression did not differ significantly between atopic and normal dog groups. By real time
RT-PCR using sections, it was impossible to determine the distribution pattern of PO mRNA. As the number of PO non-producing cells (such as lymphocytes) was increased in atopic skin compared with control skin, it was difficult to compare PO gene expression.

In summary, the author has revealed the high expression of PO in canine atopic skin. PO is produced by keratinocyte and fibroblast and may play an important role in canine atopic skin.
Figure 1. Identification of canine periostin (PO) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) transcripts in various organs by reverse transcription polymerase chain reaction (RT-PCR).

**a.** The PO mRNA was expressed in a wide range of normal canine tissue, including heart (He), lung (Lu), liver (Li), kidney (Ki), spleen (Sp), pancreas (Pa), small intestine (Si), colon (Co), ovary (Ov), testis (Te), cerebrum (Ce), mesenteric lymph node (Ly) and skin (Sk). **b.** Canine GAPDH cDNA was amplified as an internal control. M, molecular weight marker.
Figure 2. Normal skin, dog. 

a. The red color indicates a positive signal for PO mRNA (fast red) (arrow heads). The PO mRNA was expressed in the outer root sheath cells of the hair follicle, particularly in the outer cells along the basement membrane. In situ hybridization (ISH) for PO.

Inset: high-power magnification view of hair follicles, ISH for PO. Bar = 500 μm.

b. The brown color indicates positive staining for the PO protein (arrows). The PO protein was localized at the perifollicular area. Immunohistochemical staining (IHC) for PO. Inset: high-power magnification view of hair follicles, IHC for PO. Bar = 500 μm.

c. In the epidermis, PO mRNA was expressed only in the basal epidermal keratinocytes (arrows heads). ISH for PO.

d. Slight PO protein expression was observed in the dermis, just beneath the basal layer (arrows). IHC for PO.

e. No signal was observed with the PO mRNA sense probe. ISH for PO (sense probe).

f. No staining was observed with non-immune rabbit IgG. IHC for non-immune rabbit IgG. 500
Figure 3. Sebaceous adenitis, skin, dog, case No. 18. a. Isthmus perifollicular inflammation was observed. Hematoxylin and eosin (HE). Bar = 300 μm. b. PO protein expression was prominent in the perifollicular area. IHC for PO. Bar = 300 μm. c. The PO mRNA was expressed in outer root sheath cells (arrows heads) and fibroblasts surrounding hair follicles. ISH for PO. Bar = 50 μm.

Figure 4. Sterile pyogranuloma, skin, dog, case No. 32. a. Granulomatous inflammation was observed in the deep dermis and the subcutis. HE. Bar = 300 μm. b. PO was localized in inflammatory tissue. IHC for PO. Bar = 300 μm. c. The PO mRNA was expressed in fibroblasts but not in inflammatory cells. Positive signals for PO mRNA were also detected in some adipocytes. ISH for PO. Bar = 50 μm.

Figure 5. Diffuse dermatitis, skin, dog, case No. 22. a. Inflammatory cells were detected diffusely in the dermis. HE. Bar = 300 μm. b. PO protein expression was prominent throughout the dermis with inflammatory cell infiltrates. IHC for PO. Bar = 300 μm. c. The PO mRNA was expressed in
fibroblasts but not in inflammatory cells. ISH for PO. Bar = 50 μm.
Figure 6. Atopic dermatitis, skin, dog, case No. 5. a. The expression of PO was significantly elevated in the superficial dermis, particularly at the epidermal–dermal junction (arrows). IHC for PO. *Inset*: high-power magnification view of the epidermis and superficial dermis, IHC for PO. b. The PO mRNA was more prominently expressed in keratinocytes. ISH for PO. *Inset*: high-power magnification view of the epidermis and superficial dermis. c. No staining was observed with non-immune rabbit IgG. IHC for non-immune rabbit IgG. d. No signal was observed with the PO mRNA sense probe. ISH for PO (sense probe). Bar = 500 μm.
**Figure 7.** Atopic dermatitis, skin, dog, case No. 5. Epi, epidermis; Der, dermis. 

**a.** Expression of type IV collagen was detected at the epidermal–dermal junction (EDJ) (arrowheads) and vascular basement membrane (arrows). Immunofluorescence staining (IF) for type IV collagen.

**b.** Expression of laminin was detected at the EDJ (arrowheads) and vascular basement membrane (arrows). IF for laminin.

**c.** PO was more prominently expressed at the EDJ (arrowheads) and detected faintly at the vascular basement membrane. IF for PO. Bar = 100 μm.
Figure 8. PO/GAPDH mRNA rate in atopic skin (n = 5) and control skin (n = 5). The ratio of PO/GAPDH mRNA expression did not differ significantly between atopic and normal dog groups. Real time quantitative RT-PCR.
Figure 9. Correlation between distribution patterns of PO and histological severity in the skin tissues of atopic dogs. Three distribution patterns of PO of atopic dogs were as follows: basement membrane pattern, superficial pattern and diffuse pattern (compared with the healthy control, which was assigned a normal pattern). The number of inflammatory cells (CD3+, CD20+, and mast cells) in the dermis was counted in 10 high-power fields for each sample. Chronic pathological changes
(epidermal thickening and fibrosis) and the number of CD3+ cells in the skin was correlated between
some distribution patterns of PO, especially between normal and diffuse pattern. Normal, normal
pattern; BM, basement membrane pattern; Superficial, superficial pattern; Diffuse, diffuse pattern.
(*p < 0.05, **p < 0.01, ***p < 0.001; one-way ANOVA). a. Epidermal thickness was measured in
10 high-power fields for each sample. A significant positive correlation was observed between
epidermal thickness and PO patterns b. Correlation between fibrosis scores and PO patterns. c.
Correlation between the number of CD3-positive cells (T cells) and PO patterns. d. Correlation
between the number of CD20-positive cells (B cells) and PO patterns. e. Correlation between the
number of mast cells and PO patterns.
<table>
<thead>
<tr>
<th>Case No.</th>
<th>Site No.</th>
<th>Site</th>
<th>Breed</th>
<th>Sex/Age</th>
<th>Histological Diagnosis</th>
<th>Comprehensive diagnosis/Remarks</th>
<th>Immunohistochemical score and localization of periostin</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>EDJ</td>
</tr>
<tr>
<td>1</td>
<td>1 Face</td>
<td>Welsh Corgi</td>
<td>C/13 y</td>
<td></td>
<td>Superficial dermatitis</td>
<td>AD</td>
<td>3+</td>
</tr>
<tr>
<td></td>
<td>2 Back</td>
<td></td>
<td></td>
<td></td>
<td>Superficial dermatitis</td>
<td>AD</td>
<td>3+</td>
</tr>
<tr>
<td>2</td>
<td>3 Face</td>
<td>Shiba</td>
<td>C/11 y</td>
<td></td>
<td>Superficial dermatitis</td>
<td>AD</td>
<td>3+</td>
</tr>
<tr>
<td></td>
<td>4 Armpit</td>
<td></td>
<td></td>
<td></td>
<td>Superficial dermatitis</td>
<td>AD</td>
<td>3+</td>
</tr>
<tr>
<td></td>
<td>5 Hind leg</td>
<td></td>
<td></td>
<td></td>
<td>Superficial dermatitis</td>
<td>AD</td>
<td>3+</td>
</tr>
<tr>
<td>3</td>
<td>6 Shoulder</td>
<td>Bernese Mountain Dog</td>
<td>M/9 y</td>
<td>Superficial dermatitis</td>
<td>AD/Non-lesion</td>
<td>2+</td>
<td>2+</td>
</tr>
<tr>
<td></td>
<td>7 Abdomen</td>
<td></td>
<td></td>
<td></td>
<td>Superficial dermatitis</td>
<td>AD/lesion</td>
<td>2+</td>
</tr>
<tr>
<td></td>
<td>8 Abdomen</td>
<td></td>
<td></td>
<td></td>
<td>Superficial dermatitis</td>
<td>AD/Non-lesion</td>
<td>2+</td>
</tr>
<tr>
<td>4</td>
<td>9 Hind leg</td>
<td>Golden Retriever</td>
<td>S/10 y</td>
<td>Superficial dermatitis</td>
<td>AD</td>
<td>2+</td>
<td>2+</td>
</tr>
<tr>
<td></td>
<td>10 Abdomen</td>
<td></td>
<td></td>
<td></td>
<td>Superficial dermatitis</td>
<td>AD</td>
<td>2+</td>
</tr>
<tr>
<td>5</td>
<td>11 Abdomen</td>
<td>Shiba</td>
<td>M/8 y</td>
<td></td>
<td>Superficial dermatitis</td>
<td>AD</td>
<td>3+</td>
</tr>
<tr>
<td></td>
<td>12 Abdomen</td>
<td></td>
<td></td>
<td></td>
<td>Superficial dermatitis</td>
<td>AD</td>
<td>3+</td>
</tr>
<tr>
<td>6</td>
<td>13 Shoulder</td>
<td>Chihuahua</td>
<td>M/2 y</td>
<td></td>
<td>Superficial dermatitis</td>
<td>AD</td>
<td>2+</td>
</tr>
<tr>
<td></td>
<td>14 Back</td>
<td></td>
<td></td>
<td></td>
<td>Superficial dermatitis</td>
<td>AD</td>
<td>3+</td>
</tr>
<tr>
<td>7</td>
<td>15 Neck</td>
<td>Shih Tzu</td>
<td>F/5 y</td>
<td></td>
<td>Superficial dermatitis</td>
<td>AD</td>
<td>3+</td>
</tr>
<tr>
<td></td>
<td>16 Armpit</td>
<td></td>
<td></td>
<td></td>
<td>Superficial dermatitis</td>
<td>AD</td>
<td>3+</td>
</tr>
<tr>
<td></td>
<td>17 Back</td>
<td></td>
<td></td>
<td></td>
<td>Superficial dermatitis</td>
<td>AD</td>
<td>2+</td>
</tr>
<tr>
<td>8</td>
<td>18 Back</td>
<td>Yorkshire Terrier</td>
<td>S/8 y</td>
<td>Superficial dermatitis</td>
<td>AD</td>
<td>2+</td>
<td>1+</td>
</tr>
<tr>
<td></td>
<td>19 Abdomen</td>
<td>Standard Poodle</td>
<td>M/4 y</td>
<td>Superficial dermatitis</td>
<td>AD</td>
<td>2+</td>
<td>2+</td>
</tr>
<tr>
<td>9</td>
<td>20 Abdomen</td>
<td>Papillon</td>
<td>S/10 y</td>
<td>Superficial dermatitis</td>
<td>Superficial pyoderma</td>
<td>2+</td>
<td>2+</td>
</tr>
<tr>
<td></td>
<td>21 Hind leg</td>
<td></td>
<td></td>
<td></td>
<td>Superficial dermatitis</td>
<td>Superficial pyoderma</td>
<td>2+</td>
</tr>
<tr>
<td>10</td>
<td>22 Hip</td>
<td>Shetland Sheepdog</td>
<td>M/12 y</td>
<td>Superficial dermatitis</td>
<td>Superficial pyoderma/Lesion</td>
<td>3+</td>
<td>2+</td>
</tr>
<tr>
<td></td>
<td>23 Hip</td>
<td></td>
<td></td>
<td></td>
<td>Superficial dermatitis</td>
<td>Superficial pyoderma/Non-lesion</td>
<td>2+</td>
</tr>
</tbody>
</table>
Table 1. Characteristics of dogs with skin diseases and the results of immunohistochemical examinations of skin diseases. (continue)

<table>
<thead>
<tr>
<th>Case No.</th>
<th>Site No.</th>
<th>Site</th>
<th>Breed</th>
<th>Sex/Age</th>
<th>Histological Diagnosis</th>
<th>Comprehensive diagnosis/Remarks</th>
<th>Immunohistochemical score and localization of periostin</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>EDJ</td>
</tr>
<tr>
<td>12</td>
<td>24</td>
<td>Back</td>
<td>Golden Retriever</td>
<td>M/13 y</td>
<td>Demodicosis</td>
<td>Demodicosis</td>
<td>3+</td>
</tr>
<tr>
<td>13</td>
<td>25</td>
<td>Abdomen</td>
<td>Miniature Dachshund</td>
<td>C/10 y</td>
<td>Superficial dermatitis</td>
<td>Pemphigus foliaceus</td>
<td>2+</td>
</tr>
<tr>
<td>14</td>
<td>26</td>
<td>Abdomen</td>
<td>Miniature Dachshund</td>
<td>S/14 y</td>
<td>Superficial dermatitis</td>
<td>Pemphigus foliaceus</td>
<td>2+</td>
</tr>
<tr>
<td>15</td>
<td>27</td>
<td>Back</td>
<td>Miniature Dachshund</td>
<td>S/14 y</td>
<td>Superficial dermatitis</td>
<td>Pemphigus foliaceus</td>
<td>3+</td>
</tr>
<tr>
<td>16</td>
<td>28</td>
<td>Hip</td>
<td>Toy Poodle</td>
<td>S/2 y</td>
<td>Superficial dermatitis</td>
<td>Unconfirmed</td>
<td>2+</td>
</tr>
<tr>
<td>17</td>
<td>29</td>
<td>Neck</td>
<td>Toy Poodle</td>
<td>S/2 y</td>
<td>Superficial dermatitis</td>
<td>Unconfirmed</td>
<td>2+</td>
</tr>
<tr>
<td>18</td>
<td>30</td>
<td>Back</td>
<td>Toy Poodle</td>
<td>S/2 y</td>
<td>Superficial dermatitis</td>
<td>Unconfirmed</td>
<td>2+</td>
</tr>
<tr>
<td>19</td>
<td>31</td>
<td>Face</td>
<td>Maltese</td>
<td>M/8 y</td>
<td>Superficial dermatitis</td>
<td>Not AD</td>
<td>2+</td>
</tr>
<tr>
<td>20</td>
<td>32</td>
<td>Unknown</td>
<td>Akita</td>
<td>S/5 y</td>
<td>Sebaceous adenitis</td>
<td>Sebaceous adenitis</td>
<td>1+</td>
</tr>
<tr>
<td>21</td>
<td>33</td>
<td>Back</td>
<td>Mixed</td>
<td>M/5 y</td>
<td>Sebaceous adenitis</td>
<td>Sebaceous adenitis</td>
<td>2+</td>
</tr>
<tr>
<td>22</td>
<td>34</td>
<td>Back</td>
<td>Akita</td>
<td>M/5 y</td>
<td>Sebaceous adenitis</td>
<td>Sebaceous adenitis</td>
<td>1+</td>
</tr>
<tr>
<td>23</td>
<td>35</td>
<td>Back</td>
<td>Akita</td>
<td>M/7 y</td>
<td>Sebaceous adenitis</td>
<td>Sebaceous adenitis</td>
<td>3+</td>
</tr>
<tr>
<td>24</td>
<td>36</td>
<td>Face</td>
<td>Shiba</td>
<td>S/1 y</td>
<td>Diffuse dermatitis</td>
<td>Deep pyoderma</td>
<td>2+</td>
</tr>
<tr>
<td>25</td>
<td>37</td>
<td>Nail bed</td>
<td>French Bulldog</td>
<td>S/5 y</td>
<td>Diffuse dermatitis</td>
<td>Deep pyoderma</td>
<td>1+</td>
</tr>
<tr>
<td>26</td>
<td>38</td>
<td>Face</td>
<td>Mixed</td>
<td>F/4 y</td>
<td>Diffuse dermatitis</td>
<td>Unconfirmed</td>
<td>3+</td>
</tr>
<tr>
<td>27</td>
<td>39</td>
<td>Face</td>
<td>Pomeranian</td>
<td>C/3 y</td>
<td>Diffuse dermatitis</td>
<td>Unconfirmed</td>
<td>1+</td>
</tr>
<tr>
<td>28</td>
<td>40</td>
<td>Face</td>
<td>Akita</td>
<td>C/10 y</td>
<td>Diffuse dermatitis</td>
<td>Unconfirmed</td>
<td>2+</td>
</tr>
<tr>
<td>29</td>
<td>41</td>
<td>Nail bed</td>
<td>Mixed</td>
<td>M/15 y</td>
<td>Inflammatory granulation tissue</td>
<td>Unconfirmed</td>
<td>1+</td>
</tr>
<tr>
<td>30</td>
<td>42</td>
<td>Back</td>
<td>Miniature Dachshund</td>
<td>C/11 y</td>
<td>Interface dermatitis</td>
<td>Lesion</td>
<td>2+</td>
</tr>
<tr>
<td>31</td>
<td>43</td>
<td>Back</td>
<td>Interface dermatitis</td>
<td>Non-lesion</td>
<td>2+</td>
<td>2+</td>
<td>0</td>
</tr>
<tr>
<td>32</td>
<td>44</td>
<td>Back</td>
<td>Mixed</td>
<td>F/17 y</td>
<td>Interface dermatitis</td>
<td>Unconfirmed</td>
<td>1+</td>
</tr>
<tr>
<td>33</td>
<td>45</td>
<td>Unknown</td>
<td>Basenji</td>
<td>M/8 y</td>
<td>Interface dermatitis</td>
<td>Unconfirmed</td>
<td>1+</td>
</tr>
<tr>
<td>34</td>
<td>46</td>
<td>Back</td>
<td>Miniature Dachshund</td>
<td>M/15 y</td>
<td>Sterile pyogranuloma</td>
<td>Sterile pyogranuloma</td>
<td>1+</td>
</tr>
<tr>
<td>35</td>
<td>47</td>
<td>Back</td>
<td>Miniature Dachshund</td>
<td>C/9 y</td>
<td>Sterile pyogranuloma</td>
<td>Sterile pyogranuloma</td>
<td>2+</td>
</tr>
</tbody>
</table>
Table 1. Characteristics of dogs with skin diseases and the results of immunohistochemical examinations of skin diseases. (continue)

<table>
<thead>
<tr>
<th>Case No.</th>
<th>Site No.</th>
<th>Site</th>
<th>Breed</th>
<th>Sex/Age</th>
<th>Histological Diagnosis</th>
<th>Comprehensive diagnosis/Remarks</th>
<th>Immunochemistry score and localization of periostinb</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Comorbidity</td>
<td></td>
<td>EDJIg</td>
</tr>
<tr>
<td>33</td>
<td>48</td>
<td>Back</td>
<td>Miniature Dachshund</td>
<td>M/11 y</td>
<td>Superficial pustular dermatitis</td>
<td>Superficial pustular drug reactions</td>
<td>1+</td>
</tr>
<tr>
<td>34</td>
<td>49</td>
<td>Unknown</td>
<td>Chihuahua</td>
<td>S/3 y</td>
<td>Superficial pustular dermatitis</td>
<td>Unconfirmed</td>
<td>1+</td>
</tr>
<tr>
<td>35</td>
<td>50</td>
<td>Face</td>
<td>Shetland Sheepdog</td>
<td>M/4 m</td>
<td>Dermatomyositis</td>
<td>Dermatomyositis</td>
<td>1+</td>
</tr>
<tr>
<td>36</td>
<td>51</td>
<td>Foreleg</td>
<td>Jack Russell Terrier</td>
<td>S/2 y</td>
<td>Folliculitis</td>
<td>Unconfirmed</td>
<td>1+</td>
</tr>
<tr>
<td>37</td>
<td>52</td>
<td>Hind leg</td>
<td>French Bulldog</td>
<td>F/5 y</td>
<td>Cutaneous mastocytosis</td>
<td>Cutaneous mastocytosis</td>
<td>1+</td>
</tr>
<tr>
<td>38</td>
<td>53</td>
<td>Foreleg</td>
<td>Mixed</td>
<td>M/4 y</td>
<td>Vascularitis</td>
<td>Immune-mediated thrombocytopenia with vasculitis</td>
<td>2+</td>
</tr>
<tr>
<td>39</td>
<td>54</td>
<td>Hip</td>
<td>French Bulldog</td>
<td>C/10 y</td>
<td>Calciosis cutis</td>
<td>Calciosis cutis</td>
<td>2+</td>
</tr>
<tr>
<td>40</td>
<td>55</td>
<td>Abdomen</td>
<td>Labrador Retriever</td>
<td>S/3 y</td>
<td>Heat burn</td>
<td>Heat burn</td>
<td>2+</td>
</tr>
<tr>
<td>41</td>
<td>56</td>
<td>Abdomen</td>
<td>American Cocker Spaniel</td>
<td>S/7 y</td>
<td>Erythema cabriform</td>
<td>Erythema cabriform</td>
<td>1+</td>
</tr>
<tr>
<td>42</td>
<td>57</td>
<td>Abdomen</td>
<td>Maltese</td>
<td>F/9 y</td>
<td>Acute dermatitis</td>
<td>Unconfirmed</td>
<td>1+</td>
</tr>
<tr>
<td>43</td>
<td>58</td>
<td>Abdomen</td>
<td>Maltese</td>
<td>S/12 y</td>
<td>Acute febrile neutrophilic dermatosis</td>
<td>Sweet’s syndrome</td>
<td>1+</td>
</tr>
<tr>
<td>44</td>
<td>59</td>
<td>Unknown</td>
<td>Miniature Dachshund</td>
<td>Unknown/7 m</td>
<td>Edema</td>
<td>Unconfirmed</td>
<td>1+</td>
</tr>
<tr>
<td>45</td>
<td>60</td>
<td>Head</td>
<td>Toy Poodle</td>
<td>M/3 y</td>
<td>Folliculardysplasia</td>
<td>Follicular dysplasia</td>
<td>1+</td>
</tr>
<tr>
<td>46</td>
<td>61</td>
<td>Hind leg</td>
<td>West Highland White Terrier</td>
<td>C/7 m</td>
<td>Atrophy of hair follicles</td>
<td>Alopecia</td>
<td>1+</td>
</tr>
<tr>
<td>47</td>
<td>62</td>
<td>Hip</td>
<td>Toy Poodle</td>
<td>F/7 y</td>
<td>Atrophy of hair follicles</td>
<td>Lateralgamic cushing’s syndrome</td>
<td>1+</td>
</tr>
</tbody>
</table>

*M, male; F, female; C, castrated male; S, spayed female; y, years old; m, months old  
AD, atopic dermatitis; Unconfirmed, we could not show clinical diagnosis in some cases, because multiple differential diagnosis could be considered or we couldn’t obtain the satisfactory information from veterinary clinicians.  
0 = no expression, 1+ = mild expression, 2+ = moderate expression, 3+ = high expression in the dermis.  
EDJ, epidermal-dermal junction  
PD, perifollicular dermis  
SD, superficial dermis  
DD, deep dermis
<table>
<thead>
<tr>
<th>Antibody</th>
<th>Clone</th>
<th>Dilution</th>
<th>Source</th>
<th>Antigen retrieval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Periostin</td>
<td>Polyclonal</td>
<td>1:500</td>
<td>Abcam., Cambridge, U.K.</td>
<td>No treatment</td>
</tr>
<tr>
<td>Type IV collagen</td>
<td>Polyclonal</td>
<td>1:500</td>
<td>Tokyo University(^b)</td>
<td>Pepsin, 37°C, 30 min</td>
</tr>
<tr>
<td>Laminin</td>
<td>Polyclonal</td>
<td>1:100</td>
<td>Progen Biotechnik., Heidelberg, Germany</td>
<td>Pepsin, 37°C, 30 min</td>
</tr>
<tr>
<td>CD3</td>
<td>Polyclonal</td>
<td>1:50</td>
<td>Dako Denmark A/S., Glostrup, Denmark</td>
<td>Pepsin, 37°C, 30 min</td>
</tr>
<tr>
<td>CD20</td>
<td>Polyclonal</td>
<td>1:400</td>
<td>Thermo fisher scientific., California, U.S.A.</td>
<td>No treatment</td>
</tr>
<tr>
<td>Factor VIII-related antigen</td>
<td>Polyclonal</td>
<td>Prediluted</td>
<td>Dako Denmark A/S., Glostrup, Denmark</td>
<td>Pepsin, 37°C, 20 min</td>
</tr>
<tr>
<td>SMA(^c)</td>
<td>1A4</td>
<td>1:100</td>
<td>Dako Denmark A/S., Glostrup, Denmark</td>
<td>No treatment</td>
</tr>
</tbody>
</table>

\(^a\)Pepsin = 0.4% pepsin (Sigma-Aldrich Co., St. Louis, MO, U.S.A.) \(^b\)This antibody was kindly supplied by Dr. M. Ito and Dr. K. Arai (Department of Sickle Protein Chemistry and Cell Biology, Tokyo University of Agriculture and Technology). \(^c\)SMA = smooth muscle actin
Table 3. Histological findings and periostin immunolabeling of tissue samples from atopic dogs.

<table>
<thead>
<tr>
<th>Dog No.</th>
<th>Site</th>
<th>Epidermal thickness (μm)</th>
<th>Fibrosis</th>
<th>CD3 (cells/10 views)</th>
<th>CD20 (cells/10 views)</th>
<th>Mast cell (cells/10 views)</th>
<th>EDJ[^f]</th>
<th>PF[^f]</th>
<th>SD[^g]</th>
<th>DD[^h]</th>
<th>Periostin patterns[^i]</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Face</td>
<td>109.4</td>
<td>3+</td>
<td>395</td>
<td>222</td>
<td>110</td>
<td>3+</td>
<td>2+</td>
<td>2+</td>
<td>0</td>
<td>D</td>
</tr>
<tr>
<td>2</td>
<td>back</td>
<td>68.2</td>
<td>3+</td>
<td>519</td>
<td>604</td>
<td>79</td>
<td>3+</td>
<td>1+</td>
<td>2+</td>
<td>0</td>
<td>D</td>
</tr>
<tr>
<td>3</td>
<td>Face</td>
<td>78.2</td>
<td>2+</td>
<td>45</td>
<td>35</td>
<td>82</td>
<td>3+</td>
<td>2+</td>
<td>1+</td>
<td>0</td>
<td>S</td>
</tr>
<tr>
<td>4</td>
<td>Armpit</td>
<td>261.9</td>
<td>3+</td>
<td>64</td>
<td>20</td>
<td>117</td>
<td>3+</td>
<td>2+</td>
<td>2+</td>
<td>1+</td>
<td>D</td>
</tr>
<tr>
<td>5</td>
<td>Hind leg</td>
<td>70.5</td>
<td>1+</td>
<td>53</td>
<td>41</td>
<td>55</td>
<td>3+</td>
<td>2+</td>
<td>1+</td>
<td>0</td>
<td>S</td>
</tr>
<tr>
<td>6</td>
<td>Shoulder</td>
<td>18.7</td>
<td>0</td>
<td>2</td>
<td>6</td>
<td>15</td>
<td>2+</td>
<td>2+</td>
<td>0</td>
<td>0</td>
<td>BM</td>
</tr>
<tr>
<td>7</td>
<td>Abdomen</td>
<td>115.2</td>
<td>1+</td>
<td>462</td>
<td>455</td>
<td>283</td>
<td>2+</td>
<td>2+</td>
<td>1+</td>
<td>0</td>
<td>S</td>
</tr>
<tr>
<td>8</td>
<td>Abdomen</td>
<td>21.3</td>
<td>1+</td>
<td>17</td>
<td>22</td>
<td>12</td>
<td>2+</td>
<td>2+</td>
<td>0</td>
<td>0</td>
<td>BM</td>
</tr>
<tr>
<td>9</td>
<td>Hind leg</td>
<td>283.2</td>
<td>3+</td>
<td>192</td>
<td>27</td>
<td>217</td>
<td>2+</td>
<td>2+</td>
<td>1+</td>
<td>1+</td>
<td>D</td>
</tr>
<tr>
<td>10</td>
<td>Abdomen</td>
<td>40</td>
<td>2+</td>
<td>63</td>
<td>10</td>
<td>57</td>
<td>2+</td>
<td>2+</td>
<td>0</td>
<td>0</td>
<td>BM</td>
</tr>
<tr>
<td>11</td>
<td>Abdomen</td>
<td>95.1</td>
<td>1+</td>
<td>20</td>
<td>14</td>
<td>83</td>
<td>3+</td>
<td>2+</td>
<td>2+</td>
<td>0</td>
<td>D</td>
</tr>
<tr>
<td>12</td>
<td>Abdomen</td>
<td>41</td>
<td>1+</td>
<td>23</td>
<td>51</td>
<td>113</td>
<td>3+</td>
<td>2+</td>
<td>0</td>
<td>0</td>
<td>S</td>
</tr>
<tr>
<td>13</td>
<td>Shoulder</td>
<td>58.4</td>
<td>1+</td>
<td>159</td>
<td>3</td>
<td>161</td>
<td>2+</td>
<td>1+</td>
<td>0</td>
<td>0</td>
<td>BM</td>
</tr>
<tr>
<td>14</td>
<td>Back</td>
<td>106.3</td>
<td>1+</td>
<td>69</td>
<td>25</td>
<td>54</td>
<td>3+</td>
<td>1+</td>
<td>0</td>
<td>0</td>
<td>S</td>
</tr>
<tr>
<td>15</td>
<td>Neck</td>
<td>134</td>
<td>3+</td>
<td>82</td>
<td>5</td>
<td>40</td>
<td>3+</td>
<td>2+</td>
<td>1+</td>
<td>0</td>
<td>S</td>
</tr>
<tr>
<td>16</td>
<td>Armpit</td>
<td>102.9</td>
<td>2+</td>
<td>55</td>
<td>18</td>
<td>59</td>
<td>3+</td>
<td>2+</td>
<td>1+</td>
<td>0</td>
<td>S</td>
</tr>
<tr>
<td>17</td>
<td>Back</td>
<td>141.4</td>
<td>2+</td>
<td>68</td>
<td>17</td>
<td>53</td>
<td>2+</td>
<td>1+</td>
<td>0</td>
<td>0</td>
<td>BM</td>
</tr>
<tr>
<td>18</td>
<td>Back</td>
<td>64.1</td>
<td>2+</td>
<td>22</td>
<td>34</td>
<td>21</td>
<td>2+</td>
<td>1+</td>
<td>0</td>
<td>0</td>
<td>BM</td>
</tr>
<tr>
<td>19</td>
<td>Abdomen</td>
<td>31.9</td>
<td>1+</td>
<td>62</td>
<td>11</td>
<td>36</td>
<td>2+</td>
<td>2+</td>
<td>0</td>
<td>0</td>
<td>BM</td>
</tr>
</tbody>
</table>

Normal dog: 15.3 ± 2.7[^j] 0 ± 3.8 ± 2.0[^j] 1.2 ± 1.2[^j] 17.2 ± 3.5[^j] 1+ ± 1+ ± 0 ± N

[^j] Dogs with AD underwent 19 sites all together.[^j] Epidermal thickness, measured in 10 randomly selected fields for each sample.[^j] Semiquantitative scores for dermal fibrosis. 0 = no expression, 1+ = mild expression, 2+ = moderate expression, 3+ = high expression in the dermis.[^j] EDJ, epidermal-dermal junction.[^j] PF, perifollicular area.[^j] SD, superficial dermis.[^j] DD, deep dermis.[^j] Periostin patterns. N, normal pattern; BM, basement membrane pattern; S, superficial pattern; D, diffuse pattern.[^j] Mean ± SD
Chapter 2: Involvement of IL-13 in the Induction of Periostin, and Effect of Periostin on Keratinocytes

Introduction
From the results of Chapter 1, it was suggested that PO might be involved in the pathogenesis of chronicity in cAD. Therefore, the author tried to clarify the mechanism of the amplification and chronicity of dermal inflammation by PO in canine atopic skin in this chapter.

Firstly, the author focused on IL-13 and TGF-β1 which were assumed to be inducing factor of PO, using skin tissues of cAD as well as canine cultured keratinocytes and dermal fibroblasts. It is widely known that TGF-β is a major trigger of PO production of both dermal and pulmonary fibroblasts.[4, 24, 32] Recently, Masuoka et al.[14] reported that IL-13 induced PO production in the skin of a murine atopic model independently of TGF-β.

Next, the author examined the function of PO using culture canine keratinocytes by proliferation assay, microarray and real time quantitative RT-PCR. The keratinocytes acts as major immune cells as well as a mechanical barrier between the external environment and the body.[10, 12] Previous studies have reported that cytokines and chemokines such as thymus and activation-regulated chemokine (TARC/CCL17) are exclusively produced by keratinocytes in human and canine atopic skin.[10, 12] From the results of immunohistochemistry in Chapter 1, the author assumed that PO might involve the epidermal thickening and infiltration of
inflammatory cells which are major pathologic features in canine atopic skin.

Finally, the author discussed the possible involvement of PO in the pathophysiology of cAD.

Materials and Methods

Double-In situ hybridization

Double-ISH for PO and IL-13/TGF-β1 was performed using the QuantiGene® ViewRNA ISH Tissue Assay according to the manufacturer’s protocol, as described Chapter 1. PO probes were used in type 1/Fast Red, and IL-13 and TGF-β1 were used in type 6/Fast Blue. Double-ISH sections were counterstained with Mayer’s hematoxylin.

Cell culture of canine keratinocytes and dermal fibroblasts

The author used two types of culture cells, commercially available canine keratinocyte cell line (CPEK, CELLnTEC Advanced Cell Systems, Bern, Switzerland) and canine dermal fibroblasts. CPEK was cultured in 25 cm² flasks (AGC TECHNO GLASS CO., LTD., Shizuoka, Japan) in CnT-09 (CELLnTEC Advanced Cell Systems) with 10% fetal bovine serum (FBS; Hana-nesco Bio. Co., Tokyo, Japan) and 1% Antibiotic Antimycotic (Thermo Fisher Scientific Inc., Waltham, MA) until approximately 80% confluence at 37 °C under 5% CO2. The cultured cells were trypsinized by treatment with 2 ml Trypsin-EDTA and incubated for 7–10 min at 37 °C. Fifth- to tenth-passage CPEK was used in these experiments.
Primary culture of canine dermal fibroblasts was performed according to the previous report [1] for the human skin. Briefly, full-depth skin samples obtained from the chest region of normal dogs were immediately placed in PBS (pH 7.2, 0.01 M) with 1% Antibiotic Antimycotic. Skin samples were rinsed seven times with PBS. Then skin samples were fragmented into 5 mm² pieces. These skin fragments were laid onto the surface of 60 mm x 15mm Petri dishes with Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 (DMEM/F12, 1:1; Invitrogen Life Technologies) containing of 10% fetal bovine serum and 1% Antibiotic Antimycotic. Cultures were incubated at 37°C in a humidified incubator with 5% CO₂. The culture medium was changed every three days. Satisfactory proliferation of fibroblasts was observed in approximately twenty days. Fibroblasts of 3rd to 5th passages were used for the experiments.

Real time quantitative RT-PCR

CPEK and dermal fibroblasts were grown in 24-well plates (AGC TECHNO GLASS CO., LTD.); after washing with PBS to remove all sera, then the cells were serum-starved for 24hrs.

For real time quantitative RT-PCR analysis to estimate PO mRNA expression, CPEK and fibroblasts were cultured in DMEM/F12 with or without 50ng/μL recombinant canine IL-13 (rcIL-13: R&D Systems, Minneapolis, MN) for 6 or 24 hrs. CPEK were cultured in DMEM/F12
with or without 2µg/mL recombinant human PO (rhPO, R&D Systems) for 2, 6, 12, 24 or 36 hrs.

After stimulation by rcIL-13 or rhPO, total RNA was extracted from cell cultures using the RNeasy Plus Micro Kit. Extracted total RNA was used for RT-PCR employing the SuperScript® VILO™ cDNA Synthesis Kit. Quantification of mRNA expression was performed using StepOne™ Real-Time PCR Systems, TaqMan Universal PCR Master Mix and TaqMan MGB probe for the target genes: PO, GAPDH, IL-25 (assay ID, Cf02643291_m1), keratinocyte differentiation-associated protein (KDAP) (assay ID, Cf02680558_m1), as described in Chapter 1. The PCR reaction was performed in duplicate for each sample and mean values of the target gene expression were calculated as a ratio to those of GAPDH according to the ΔΔCT method.

**Proliferation Assay**

For proliferation assay, CPEK was cultured in with DMEM/F12 supplemented with 0.1% FBS and either rhPO (1 or 4µg/mL) dissolved in PBS or PBS alone for 24 hrs. After stimulation, proliferation assay was performed using a cell-counting kit-8 (CCK-8; Dojindo Molecular Technologies, Kumamoto, Japan) according to the manufacturer’s protocol.[11]
**Microarray**

For DNA microarray analysis, CPEK was cultured with or without 4µg/mL rhPO for 6 or 24 hrs. After stimulation by rhPO, total RNA was extracted from cell cultures using the RNeasy Plus Micro Kit. The microarray analyses were done by DNA Chip Research Inc. (Yokohama, Japan) using the Canine (V2) Gene Expression Microarray (4x44k, two-color array) according to Agilent microarray DNA chip analysis. cRNA was synthesized from the mRNA component of total cellular RNA. Each cRNA sample was then independently labeled with Cy3 (green) and Cy5 (red). The fold change was calculated for samples to represent a ratio of expression between stimulated and unstimulated control samples.

**Statistical analyses**

Statistical analyses in real time quantitative RT-PCR and proliferation assay were performed using GraphPad Prism. Comparisons of mRNA between extracted samples from stimulated and unstimulated cells were performed by the unpaired T test. P values of <0.05 were considered statistically significant.

**Results**

*IL-13 mRNA positive cells were present near the PO mRNA-positive cells.*

By Double-ISH, the IL-13 mRNA-positive small round cells were detected around the PO
mRNA-positive keratinocytes and fibroblasts in the dermis of atopic skin (Figure 10). TGF-β1 mRNA-positive cell was not seen in all atopic skins.

*IL-13 stimulated both keratinocytes and fibroblasts to produce PO.*

By *in vitro* experiments, following 6 and 24hr treatment of rcIL-13, expression of PO mRNA in keratinocytes was significant increased compared with unstimulated cells (Figure 11a). Following 24hr treatment of rcIL-13, expression of PO mRNA in dermal fibroblasts was significant increased compared with unstimulated cells (Figure 11b).

*PO enhanced in vitro growth of canine keratinocyte cell.*

The effect of PO on growth of keratinocytes was evaluated using CPEK. *In vitro* growth of CPEK was enhanced by 4µg/ml of PO treatment (Figure 12).

*PO induced gene expression of IL-25 and KDAP of canine keratinocyte cell.*

The microarray data discussed in this article have been deposited in NCBI's Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) and are accessible through GEO Series accession number GSE77041. Among these genes, the author focused on IL-25 and KDAP, because previous studies reported that these genes were shown to be overexpressed in chronic
allergic dermatitis.[9, 30]

For validation of microarray results, the author performed real time quantitative RT-PCR for the IL-25 and KDAP. Following 36hr treatment with rhPO, expression of IL-25 mRNA in keratinocytes was significant increased compared with an unstimulated cells (Figures 13). Following 2hr treatment with rhPO, expression of KDAP mRNA in keratinocytes was significant increased compared with an unstimulated cells (Figures 14).

Discussion

Previous studies have shown that cAD is associated with overproduction of Th2 cytokines such as IL-13.[18, 21, 23] By double-labeled ISH, IL-13 mRNA positive cells suspected as lymphocytes were detected near the keratinocytes and dermal fibroblasts expressing PO mRNA in canine atopic skin. This indicates close relationship between these two types of cells in canine atopic skin. These results strongly suggest that IL-13 induce PO production in keratinocytes and dermal fibroblasts in canine atopic skin independently of TGF-β1. To the best of my knowledge, this paper was the first report indicating the relationship between PO and IL-13 in spontaneous atopic skin.

The author revealed a part of functional roles of PO to induce the enhancement and chronicity in canine atopic skin by in vitro experiments. Firstly, the author confirmed that rhPO enhanced in vitro growth of canine keratinocyte cell. Moreover, among the PO-induced genes detected by
microarray, the author firstly identified IL-25 and KDAP as possible mediators in spontaneous atopic skin. Because, qRT-PCR analysis revealed up-regulation of both IL-25 and KDAP gene expression in PO-stimulated keratinocytes compared to unstimulated control.

IL-25 (also known as IL-17E) is important for Th2-mediated immunity in a murine model of asthma, and induces the impaired skin barrier observed in AD patients.[5, 9, 28] The level of IL-25 mRNA has been revealed to be elevated in the lungs of asthmatic patients and in the skins of hAD patients).[28] Furthermore, compared to PO wild-type mice, PO null mice showed amelioration of in HDM-induced inflammation and mucous metaplasia, as well as reduced Th2 cytokines including IL-25 mRNA expression.[2] Together with these previous studies, the author suspects that PO enhances Th2-immunoreaction via IL-25 signaling in canine atopic skin.

PO has been reported to play a role to enhance proliferation and differentiation of keratinocytes by in vitro and in vivo experiments. Deficiency or blockage of PO suppressed acanthosis by transdermal treatment with HDM extract in atopic model mice. In the present study, for validation of microarray results, we performed quantitative RT-PCR analysis, and found temporary up-regulation of keratinocyte differentiation-associated protein (KDAP) gene expression in rPO-stimulated keratinocytes compared to unstimulated control at 2 hr after sensitization (Supplemental material 2). KDAP (encoded by KRTDAP) is a recently identified
secretory protein that may play as a soluble regulator for the differentiation of keratinocytes. Yagihara et al.[30] reported that KDAP was more widely spread in the spinous layers of the epidermis in chronic allergic dermatitis compared to normal skin in dogs. Acanthosis is a typical histopathological features of hAD and cAD. We suspected that KDAP induced by PO may play a role in acanthosis of canine atopic skins.

Despite treatment with inhaled glucocorticoids or cyclosporin, several dogs of cAD continue to have uncontrolled skin lesion that requires more intensive therapy.[17] PO may contribute to the enhancement and chronicity of allergic skin inflammation by activating keratinocytes and dermal fibroblasts in the absence of environmental allergens as shown in the study. Corren et al.[3] examined patients with poorly controlled asthma treated with lebrikizumab, which is a monoclonal antibody to IL-13. Patients with high pretreatment levels of serum PO had greater clinical improvement than patients with low PO levels. Furthermore, the serum levels of PO were significantly elevated in hAD patients compared with controls.[14] These facts suggest close relationship between IL-13 and PO in hAD.

The author suspects that PO may play an important role in the pathophysiology of cAD. The data in this study suggest that IL-13 possibly derived from Th2 cells stimulates PO production in both keratinocytes and fibroblasts, and then PO may contribute to the enhancement and chronicity of cAD via IL-25 and KDAP (Figure 15). The findings of the present study provide a
molecular basis for considering AD. Based on the results of this study, further *in vivo* studies using experimental atopic dogs may provide novel therapeutic targets focusing on PO, IL-13 and IL-25 for AD.
**Figure 10.** Atopic dermatitis, skin, dog, case No. 5. The interleukin (IL)-13 mRNA-positive cells (arrows) are detected around the PO mRNA-positive cells in the atopic skin. Double-ISH for PO and IL-13. Bar = 50 μm.
Figure 11. Recombinant IL-13 induced expression of PO mRNA in both canine dermal fibroblasts and keratinocytes. Quantitative analysis of mRNA levels of PO in the cultured keratinocytes and dermal fibroblasts at the indicated time 6 and 24 hrs after sensitization with IL-13. a. Following both 6 and 24hrs of IL-13 treatment, PO mRNA expression in keratinocytes was significant increased compared with vehicle control. b. Following 24hr of IL-13 treatment, PO mRNA expression in dermal fibroblasts was significant increased compared with vehicle control. Real time quantitative RT-PCR (**P < 0.01, ***P < 0.001; vs vehicle control; unpaired t-test).
Figure 12. Proliferation assay of canine keratinocyte cell line (CPEK) with or without recombinant PO. *In vitro* growth of CPEK was enhanced by 4µg/ml of PO treatment (*P < 0.05, vs vehicle control; unpaired t-test).
**Figure 13.** Recombinant PO induced expression of IL-25 mRNA in canine keratinocytes.

Quantitative analysis of mRNA levels of PO in the cultured keratinocytes at the indicated time 2, 6, 12, 24 and 36 hrs after sensitization with PO. Following 36 hrs of PO treatment, IL-25 mRNA expression in keratinocytes was significant increased compared with vehicle control. Real time quantitative RT-PCR (**P < 0.01; vs vehicle control; unpaired t-test).
Figure 14. Recombinant IL-PO induced expression of KDAP mRNA in canine keratinocytes.

Quantitative analysis of mRNA levels of PO in the cultured keratinocytes and dermal fibroblasts at the indicated time 2, 6, 12, 24 and 36 hrs after sensitization with PO. Following 2hrs of PO treatment, KDAP mRNA expression in keratinocytes was significant increased compared with vehicle control. Real time quantitative RT-PCR (*P < 0.05; vs vehicle control; unpaired t-test).
Figure 15. The schema indicates hypothesis on the chronicity of inflammation via PO in atopic skin. The data in this study suggest that IL-13\(^1\) possibly derived from Th2 cells stimulates PO production\(^2\) in both keratinocytes and fibroblasts, and then PO\(^3\) may be involved a critical role in the enhancement and chronicity of cAD via IL-25 and KDAP\(^4\). APCs, antigen-presenting cells.
Conclusion

The author proposed a novel hypothesis that PO contributes to enhancement and chronicity of allergic skin inflammation in canine atopic skin. The new findings on cAD from this study are summarized as follows.

1. Canine atopic skin characteristically showed intense expression of PO in the superficial dermis. The severity score of chronic pathological changes and CD3+ cell number in the dermis were correlated with distribution pattern of PO in the canine atopic skin. These results indicated that PO could play a role in the pathophysiology of cAD.

2. ISH showed that fibroblasts and keratinocytes were the main source of PO in cAD. To the best of our knowledge, to date, no reports have focused on PO production by keratinocytes in both human and canine atopic skin.

3. By double-labeled ISH, IL-13 mRNA positive cells were detected near the keratinocytes and fibroblasts expressing PO mRNA in the dermis of atopic skin. TGF-β1 mRNA positive cell was not seen in all atopic skins. By in vitro assay, IL-13 induced the gene expression of PO in both canine dermal fibroblasts and keratinocytes. These results indicated that IL-13 induce PO production in keratinocytes and dermal fibroblasts in canine atopic skin independently of
TGF-β1.

4. PO enhanced *in vitro* growth of canine keratinocytes, suggesting that PO could be an important factor of pathogenesis of acanthosis in cAD.

5. PO induced gene expression of IL-25 and KDAP of canine keratinocyte cell. The author suggested IL-25 and KDAP as possible mediators in canine atopic skin.

In summary, the author proposes that IL-13 possibly derived from Th2 cells stimulates PO production in both keratinocytes and fibroblasts, and then PO may play a critical role in the pathophysiology of cAD, especially in the enhancement and chronicity of skin lesion via IL-25 and KDAP. The findings of the present study provide a molecular basis for considering PO and IL-13 as a potential therapeutic targets for cAD.
Acknowledgements

The author wishes to express his sincere appreciation and gratitude to Dr. Kinji Shirota, Professor of Veterinary Pathology, Azabu University, for his valuable guidance and encouragement for 4 years, as well as critical review of this thesis, as a supervisor.

The author thanks Dr. Junichi Kamiie, Veterinary Pathology, Azabu University, for his valuable advices and technical teaching in all experiments. The author also sincerely appreciates Dr. Masaharu Hisasue, Laboratory of Internal Medicine 2, Azabu University, for his valuable advices. The author also sincerely appreciates Dr. Kikumi Ogihara, Laboratory of Environmental Pathology, Azabu University, for her valuable teaching on manipulation and techniques about cultured cells. The author also thanks Dr. Sadatoshi Maeda, Department of Veterinary Internal Medicine, Gifu University and Dr. Mariko Shirota, Department of Comparative Toxicology, Azabu University for their valuable advice regarding quantitative PCR methods. The author thanks Dr. Kyohei Yasuno, Dr. Yoko Kakinuma and Ms. Yuka Isayama at Azabu University for their excellent assistance. This study was supported by many veterinary clinicians and the authors are especially thankful to Dr. Kentaro Yamagishi, Hongo Animal Hospital, Dr. Tamio Ohmuro, Ohmuro Veterinary Clinic, and Dr. Fumio Suetsugu, Maria Pet Clinic.

Thanks are also due to all graduate and undergraduate students of the author’s laboratory, especially Dr. Go Sugahara and Dr. Naoyuki Aihara, for their correct advice and kind support. I
would like to express gratitude to my colleague in graduate school for their friendly support.

A part of this thesis was published as a following article.

References


